PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14695171-6	2003	Cells not expressing CHFR showed impaired checkpoint function, which led to nuclear localization of cyclin B1 after treatment with docetaxel or paclitaxel, two microtubule inhibitors.	Docetaxel	131-140	checkpoint with forkhead and ring finger domains	Homo sapiens	21-25	
25821560-0	2015	Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel.	Docetaxel	66-75	checkpoint with forkhead and ring finger domains	Homo sapiens	15-19	
24748501-10	2015	In docetaxel-treated gastric cancer patients, resistance to docetaxel was found in CHFR unmethylated patients by Cox proportional hazards model (HR 0.243, 95% CI, 0.069-0.859, p = 0.028), and overall survival is longer in the CHFR methylated group compared with the CHFR unmethylated group (log-rank, p = 0.036).	Docetaxel	3-12	checkpoint with forkhead and ring finger domains	Homo sapiens	83-87	
24748501-10	2015	In docetaxel-treated gastric cancer patients, resistance to docetaxel was found in CHFR unmethylated patients by Cox proportional hazards model (HR 0.243, 95% CI, 0.069-0.859, p = 0.028), and overall survival is longer in the CHFR methylated group compared with the CHFR unmethylated group (log-rank, p = 0.036).	Docetaxel	3-12	checkpoint with forkhead and ring finger domains	Homo sapiens	226-230	
24748501-10	2015	In docetaxel-treated gastric cancer patients, resistance to docetaxel was found in CHFR unmethylated patients by Cox proportional hazards model (HR 0.243, 95% CI, 0.069-0.859, p = 0.028), and overall survival is longer in the CHFR methylated group compared with the CHFR unmethylated group (log-rank, p = 0.036).	Docetaxel	3-12	checkpoint with forkhead and ring finger domains	Homo sapiens	226-230	
24748501-10	2015	In docetaxel-treated gastric cancer patients, resistance to docetaxel was found in CHFR unmethylated patients by Cox proportional hazards model (HR 0.243, 95% CI, 0.069-0.859, p = 0.028), and overall survival is longer in the CHFR methylated group compared with the CHFR unmethylated group (log-rank, p = 0.036).	Docetaxel	60-69	checkpoint with forkhead and ring finger domains	Homo sapiens	83-87	
24748501-10	2015	In docetaxel-treated gastric cancer patients, resistance to docetaxel was found in CHFR unmethylated patients by Cox proportional hazards model (HR 0.243, 95% CI, 0.069-0.859, p = 0.028), and overall survival is longer in the CHFR methylated group compared with the CHFR unmethylated group (log-rank, p = 0.036).	Docetaxel	60-69	checkpoint with forkhead and ring finger domains	Homo sapiens	226-230	
24748501-10	2015	In docetaxel-treated gastric cancer patients, resistance to docetaxel was found in CHFR unmethylated patients by Cox proportional hazards model (HR 0.243, 95% CI, 0.069-0.859, p = 0.028), and overall survival is longer in the CHFR methylated group compared with the CHFR unmethylated group (log-rank, p = 0.036).	Docetaxel	60-69	checkpoint with forkhead and ring finger domains	Homo sapiens	226-230	
24748501-12	2015	CONCLUSIONS: CHFR is frequently methylated in human gastric cancer, and CHFR methylation may serve as a docetaxel-sensitive marker.	Docetaxel	104-113	checkpoint with forkhead and ring finger domains	Homo sapiens	72-76	
33811727-2	2021	We also showed that CHFR methylation predicted for sensitivity to docetaxel, whereas the MSI-high phenotypes were sensitive to gemcitabine.	Docetaxel	66-75	checkpoint with forkhead and ring finger domains	Homo sapiens	20-24	
33811727-4	2021	We enrolled a Phase 2 trial of gemcitabine and docetaxel in patients with MSI-high and/or CHFR methylated CRC.	Docetaxel	47-56	checkpoint with forkhead and ring finger domains	Homo sapiens	90-94	
29344247-11	2017	Docetaxel-induced apoptosis was inhibited in Capan-1 cells with CHFR-overexpression.	Docetaxel	0-9	checkpoint with forkhead and ring finger domains	Homo sapiens	64-68	
25821560-5	2015	When treated with docetaxel or paclitaxel, cell viability was lower in CHFR methylated esophageal cancer cells than in unmethylated cells (p<0.05).	Docetaxel	18-27	checkpoint with forkhead and ring finger domains	Homo sapiens	71-75	
25821560-7	2015	In CHFR methylated cells, treatment with docetaxel or paclitaxel resulted in almost all cells being suspended in G0/G1 phase of the cell cycle.	Docetaxel	41-50	checkpoint with forkhead and ring finger domains	Homo sapiens	3-7	
23873170-10	2014	CHFR methylation in CRC cell lines predicted for sensitivity in vitro and in vivo to docetaxel, while MSI-H cell lines were more sensitive to gemcitabine.	Docetaxel	85-94	checkpoint with forkhead and ring finger domains	Homo sapiens	0-4	
23873170-0	2014	CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.	Docetaxel	96-105	checkpoint with forkhead and ring finger domains	Homo sapiens	0-4